Method for measuring ldl aggregation
AssigneeJenny and Antti Wihuri Foundation
InventorsKatariina Öörni, Maija Ruuth, Petri Kovanen
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a method for measuring aggregation of low-density lipoprotein (LDL). The susceptibility of LDL to aggregate is an important factor regarding prognosis, diagnosis and surveillance of atherosclerotic cardiovascular diseases and cardiometabolic diseases, such as type 2 diabetes and related conditions, at various stages of their development. Also provided are methods of treatment of such diseases in subjects in need thereof.
Claims11
A method comprising:
- providing LDL particles from a human blood plasma or serum sample;
- mixing the LDL particles with a sphingomyelinase enzyme in a solution at acidic pH;
- detecting formation of LDL aggregates in the solution, and
- measuring the size of the detected LDL aggregates.
A method comprising:
- providing a human plasma or serum sample;
- mixing the human plasma or serum sample with a sphingomyelinase enzyme at acidic pH;
- detecting formation of LDL aggregates in the sample, and
- measuring the size of the detected LDL aggregates.
A method of treating an atherosclerotic cardiovascular disease or a cardiometabolic disease in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of a cholesterol lowering medication, wherein LDL particles from a blood plasma or serum sample of the human subject upon treatment with sphingomyelinase enzyme at acidic pH has been determined to form LDL aggregates that have a median size of at least 200 nm.
A method of treating an atherosclerotic cardiovascular disease or a condition associated with LDL aggregation in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of a cholesterol lowering medication, wherein LDL particles from a blood plasma or serum sample of the human subject upon treatment with sphingomyelinase enzyme at acidic pH has been determined to form LDL aggregates that have a median size of at least 200 nm.
A method of treatment comprising:
- providing LDL particles from a human blood plasma sample of a human subject;
- mixing the LDL particles with sphingomyelinase enzyme in a solution at acidic pH;
- detecting formation of LDL aggregates in said solution;
- measuring the size of the detected LDL aggregates, and
- administering to the human subject a therapeutically effective amount of a cholesterol lowering medication.
A method comprising:
- providing a human serum sample;
- mixing the human serum sample with a sphingomyelinase enzyme at acidic pH;
- detecting formation of LDL aggregates in the sample,
- measuring the size of the detected LDL aggregates, and
- administering to the human subject a therapeutically effective amount of a cholesterol lowering medication.
A method comprising:
- providing LDL particles from a human blood plasma sample of a human subject that has been taking a HMG CoA reductase inhibitor, a selective cholesterol absorption inhibitor, or a bile-acid binding resin;
- mixing the LDL particles with sphingomyelinase enzyme in a solution at acidic pH;
- detecting formation of LDL aggregates in said solution;
- measuring the size of the detected LDL aggregates;
- and
- if the LDL aggregates have a median size of at least 500 nm, continue administering to the human subject a therapeutically effective amount of the HMG CoA reductase inhibitor, selective cholesterol absorption inhibitor, or bile-acid binding resin;
- and
- if the LDL aggregates have a median size of below 500 nm, discontinue administration of the HMG CoA reductase inhibitor, selective cholesterol absorption inhibitor, or bile-acid binding resin and administer a medication selected from the group consisting of a healthy (Nordic) diet, a low sucrose diet, and a PCSK9 inhibitor, or continue administering to the human subject a therapeutically effective amount of the cholesterol lowering medication in combination with a medication selected from the group consisting of a healthy (Nordic) diet, a low sucrose diet, and a PCSK9 inhibitor.
Dependencies are inferred from the claim text.